News
A Groundbreaking Discovery for Hemophilia Research
Health and Well Being, Industry News & Research
Biochemist Gordon Vehar, PhD, vice president of external innovation at BioMarin Pharmaceutical Inc., has been at the forefront of a scientific revolution….
NHF’s Dr. Leonard Valentino Addresses COVID-19, Vaccines and Collaborative Progress
COVID-19, Industry News & Research
You have been reaching out to us with your questions and concerns about the COVID-19 vaccines and we are grateful that you…
Learn More About the COVID-19 Vaccines and ITP
COVID-19, Industry News & Research
The Platelet Disorder Support Association recently recorded a patient education webinar on the new COVID-19 vaccines and immune thrombocytopenic purpura (ITP) As…
uniQure Announces Findings from HCC Case Investigation in HOPE-B Trial for Gene Therapy
Industry News & Research
The focus of the HOPE-B trial is etranacogene dezaparvovec, uniQure’s investigational gene therapy candidate for individuals with severe and moderately severe hemophilia…
The Impact of Copay Accumulator Adjuster Programs on Patients
Industry News & Research
In the age of high deductibles and patient out-of-pocket expenditures, more and more people depend on copay assistance to afford their life-saving…
Spark Announces Preliminary Data from Investigational Gene Therapy Trial
Industry News & Research
Spark Therapeutics announced preliminary data from part one of their ongoing phase 1/2 open-label, non-randomized, dose-finding study of SPK-8016, the company’s investigational…
Sanofi Revises Fitusiran Dosing Regimen to Mitigate Risk
Industry News & Research
Source: Joint statement from the European Hemophilia Consortium, the World Federation of Hemophilia, and the National Hemophilia Foundation Fitusiran update following EAHAD…
Video: The State of Copay Accumulator Adjustment
Industry News & Research
In this video, Kollet Koulianos from NHF’s Payer Relations team explains the significance of copay Accumulator Adjustment programs. Watch now. Source: National…
19 Recommendations for Better Diagnosis and Treatment of VWD
Industry News & Research
The guidelines were developed by panels of 32 individuals, including hematologists, people living with VWD, and scientists with expertise in guideline development…
BioMarin Announces Positive Phase 3 Study Data for Valoctocogene Roxaparvovec
Industry News & Research
The phase 3 trial currently includes 134 participants with hemophilia A, all of whom have received a single dose of the gene…
President Trump Signs FY21 Federal Funding Bill Including Hemophilia SNF Access Act and Funding for Bleeding Disorders Programs
Advocacy & Legislation, COVID-19, Health and Well Being, Industry News & Research, Living with a Bleeding Disorder
The Consolidated Omnibus Appropriations Bill, 2021, signed into law by President Trump on December 27, 2020 included a number of provisions important…
NHF Offers Weekly Webinars Beginning Jan. 13 – What You Can Expect From NHF in the Upcoming Year
Industry News & Research
The National Hemophilia Foundation (NHF) will be hosting a series of weekly webinars every Wednesday at 1 p.m. CST (2 p.m. ET) beginning…
Marijuana and CBD for Chronic Pain: What You Need to Know
Health and Well Being, Industry News & Research, Living with a Bleeding Disorder
Learn about the potential benefits and risks, along with what to look out for when evaluating products. Read more hemaware.org
COVID-19: Latest News & Updates
COVID-19, Health and Well Being, Industry News & Research
Milwaukee County Updates to the COVID-19 Dashboard Since the pandemic began in March, the Milwaukee County COVID-19 dashboard has provided residents with…
Roundup of Drug Pricing Executive Orders
Advocacy & Legislation, Industry News & Research
President Trump has issued a number of executive orders on drug pricing. We show which ones could affect people with bleeding disorders….
CDC Recommends Healthcare Workers, Nursing Homes First in Line for COVID-19 Vaccine
COVID-19, Industry News & Research
The CDC is recommending that healthcare workers and residents of nursing homes be the first to receive the new coronavirus vaccines. The…
Comments From NHF’s Dr. Leonard Valentino About the COVID-19 Vaccine
COVID-19, Industry News & Research
The makers of two coronavirus vaccines, Pfizer and its German partner BioNTech, and Massachusetts-based Moderna, have applied to the FDA for emergency…
COVID-19: Latest News and Updates
COVID-19, Industry News & Research
Leaders of Wisconsin’s Two Medical Schools Urge Everyone to Take Action During the COVID-19 Outbreak. Med School Leaders Urge Public to Stay…
Patient Advocacy Organizations Release Blueprint to Protect Access to Care
Advocacy & Legislation, Industry News & Research
Thirty three organizations, including NHF, urge elected officials to ensure all people living in the US have access to adequate and affordable health…
Global Dosing Hold in Fitusiran Trials Initiated by Sanofi Genzyme to Investigate New Adverse Events
Industry News & Research
A joint statement of the World Federation of Hemophilia (WFH), European Haemophilia Consortium (EHC) and National Hemophilia Foundation (NHF). The WFH, EHC…
Patient Groups Urge U.S. Supreme Court to Prioritize Patients and Uphold Health Care Law
Advocacy & Legislation, Industry News & Research
Twenty patient groups representing millions of Americans with pre-existing conditions are urging the U.S. Supreme Court to prioritize patient protections, including those…
Access the World’s Largest Hemophilia Repository
Industry News & Research
Note: The My Life, Our Future Research Repository includes the largest bank of genomic and phenotypic data about people with hemophilia. While…
Webinar Creates Opportunity to Learn More About Rare Platelet and Bleeding Disorders!
Industry News & Research
Note: This webinar explores the diagnosis and clinical management of patients with rare inherited bleeding and platelet disorders. The National Hemophilia Foundation…
Pfizer Announces First Participant Dosed Phase 3 Study of Marstacimab
Industry News & Research
Note: Marstacimab is a laboratory-engineered monoclonal antibody developed to treat hemophilia A and B patients, with or without inhibitors. Pfizer recently announced…